Nasdaq Biotechnology Ishares (IBB) 383.01 $IBB Cramer --

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 383.01 $IBB

Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 317.44 (+8.01), GRUB: 32.26 (+1.25), XBI: 259.45 (+7.67), IBB: 383.01 (+9.43), REGN: 558.05 (+18.02), CELG: 135.86 (+3.30)

1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway   is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 113.00 (+2.46), IBB: 383.01 (+9.43), CELG: 135.86 (+3.30)

SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 4.11% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:14PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $375.96 to a high of $389.00. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $388.91 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 383.01 (+9.43)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 4.11% Sell Off
Comtex SmarTrend(R) - Fri Jul 24, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $375.96 to a high of $389.00. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $388.91 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 383.01 (+9.43)

Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
Marketwired - Thu Jul 23, 8:01AM CDT
Vista Partners announced today that it has initiated coverage on Immune Pharmaceuticals Inc. (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. ('IMNP', headquartered in New York, is a clinical stage biopharmaceutical company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. IMNP's lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with future studies planned for Crohn's disease, severe asthma, NASH and atopic dermatitis." Mr. Silver continues, "On July 14, 2015 Celgene Corporation (CELG) and Receptos, Inc. (RCPT) announced the signing of a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2B, net of cash acquired. The transaction adds Ozanimod, which has demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), among others. Having Receptos as a comparison may be beneficial to IMNP as we may now be able to understand from a monetary perspective the value a compound intended to treat UC amongst others is worth."
IBB: 383.01 (+9.43), IMNP: 1.72 (-0.02), CELGZ: 2.03 (+0.03)

iShares Nasdaq Biotechnology Index Fund (IBB) : Take profit @ $390
Trading Central - Wed Jul 15, 1:54PM CDT
A gravestone doji is taking place, calling for a trend reversal. We close our long position @ 390. Performance: +3.28%.
IBB: 383.01 (+9.43)

These 2 Biotech Stocks Cratered in 2015 -- Is 1 Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Jul 15, 9:04AM CDT
Source: Cancer Institute of Columbia For the most part, biotech stocks have been having a great 2015. The iShares Nasdaq Biotech Index , for instance, has essentially clobbered the broader markets so far this year: Per usual, however,...
IBB: 383.01 (+9.43), AAVL: 14.61 (+0.32), PBYI: 85.40 (+0.71)

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 95.07 (+0.90), FBT: 126.87 (+3.02), XBI: 259.45 (+7.67), AMGN: 173.28 (+7.74), IBB: 383.01 (+9.43), INTC: 28.94 (+0.59), CELG: 135.86 (+3.30), NFLX: 107.67 (+1.24), SPY: 209.14 (+2.35), GILD: 113.00 (+2.46), KITE: 72.01 (+3.15), RCPT: 227.75 (+0.66), JUNO: 49.06 (+1.26), TWTR: 36.02 (+1.32), AAPL: 123.51 (+0.74), Z: 79.75 (+2.84)

As Biotech Beats, 6 Top ETF Picks For Rest Of 2015
at Investor's Business Daily - Tue Jul 14, 5:38PM CDT
Biotechnology and pharmaceutical ETFs powered ahead in the past month, handing profits-on-steroids to investors. A wave of mergers, robust pipelines and busier-than-ever hospitals continue to drive these industries forward. The iShares Nasdaq...
SPY: 209.14 (+2.35), EFAV: 67.03 (+0.79), OIL: 9.40 (+0.18), AGG: 109.18 (-0.08), ILMN: 218.11 (+0.84), IBB: 383.01 (+9.43), SHY: 84.83 (-0.02), VNQ: 78.38 (+0.17), FV: 25.00 (+0.35), SDY: 76.65 (+0.72)

Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015 - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 8:30AM CDT
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015
XOP: 39.08 (+1.64), XT: 25.54 (+0.29), UBIO: 19.60 (+1.36), XBI: 259.45 (+7.67), IBB: 383.01 (+9.43), LABU: 50.58 (+4.35), ZBIO: 19.19 (-1.60), CHAD: 47.79 (-0.97), YLCO: 13.26 (-0.08), LABD: 27.57 (-2.80), DRIP: 72.11 (-11.87), ASHR: 39.86 (+0.70), GUSH: 18.06 (+1.79)

iShares Nasdaq Biotechnology Index Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 13, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 383.01 (+9.43)

Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Mon Jul 13, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 383.01 (+9.43)

It's Time for Investors to Focus on Individual Stocks, Not Macro Events
at The Street - Mon Jul 13, 1:42PM CDT
The 'Fast Money Halftime' trading panel says that in this weak macro market, momentum stocks, individual companies and specific sectors should be the theme for investors, not broad-based index funds.
FIT: 45.71 (+1.78), GREK: 9.61 (+0.28), XBI: 259.45 (+7.67), C: 58.30 (+0.34), IBB: 383.01 (+9.43), BAC: 17.83 (+0.16), TLT: 121.39 (-0.65), MS: 39.26 (+0.01), NFLX: 107.67 (+1.24), SPY: 209.14 (+2.35), GS: 205.70 (+0.68), JPM: 68.06 (+0.05), QQQ: 111.10 (+0.92), DIA: 175.97 (+1.74), IWM: 121.60 (+1.03), XLF: 25.07 (+0.13)

Trader's Notebook: Transport ETF Could Bounce Back
at The Street - Thu Jul 09, 8:00AM CDT
The iShares Transportation Average ETF (IYT) has suffered in recent months, but may finally be nearing a bit of support.
YANG: 88.33 (-3.87), IBB: 383.01 (+9.43), YINN: 28.79 (+1.13), IYT: 148.49 (+4.08), FXI: 40.67 (+0.54)

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 2.85%
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 383.01 (+9.43)

After Yesterday's Decline of 2.85%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 383.01 (+9.43)

3 Stocks to Buy in a Market Crash
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 08, 10:55AM CDT
The last five years have been an absolute dream particularly for biotech investors; shares of the  iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) have scorched the returns of the market over that time period, up more than 400% when the...
ISIS: 54.74 (+1.06), GILD: 112.98 (+2.44), IBB: 383.01 (+9.43), CELG: 135.86 (+3.30)

Uncertainty Escalates After Greek Referendum
David Fry - at Seeking Alpha - Mon Jul 06, 11:14PM CDT
At this point words fail me once again. What will happen to Greece and their EU partners, no one knows. For now it's a cancer growing on both Greece and many world stock indexes. China is more alarming after the PBOC intervened in markets to no...
XLB: 45.45 (+0.87), GREK: 9.61 (+0.28), IBB: 383.01 (+9.43), EWO: 16.38 (+0.23), TLT: 121.39 (-0.65), EEM: 36.69 (+0.33), XLP: 50.15 (+0.50), SPY: 209.14 (+2.35), ITB: 27.60 (+0.51), IYR: 74.36 (+0.25), XLI: 53.64 (+1.00), SLV: 14.02 (+0.10), FXE: 108.52 (-0.38), XLF: 25.07 (+0.13), GDX: 13.79 (+0.22), JJC: 28.37 (+0.78), XLE: 70.63 (+2.12), FXI: 40.67 (+0.54), USO: 15.92 (+0.27), DBC: 15.97 (+0.14), DBA: 21.53 (+0.20), XLY: 78.91 (+0.65), FXY: 78.58 (-0.18), EZU: 38.57 (+0.47), XLU: 43.02 (+0.15), HAO: 26.55 (+0.44), UUP: 25.29 (+0.04), XRT: 96.95 (+0.62), XLV: 75.91 (+1.13), IEV: 44.41 (+0.58), GLD: 105.04 (+0.18), EPI: 21.58 (+0.06), RSX: 16.75 (+0.23), EFA: 64.19 (+0.77), EWZ: 28.20 (+0.15)

The Medicines Company Is Rallying Despite Unfavorable Ruling In Patent Case
Emerging Equities - at Seeking Alpha - Mon Jul 06, 6:51PM CDT

MDCO: 33.79 (+0.40), MYL: 55.62 (-0.75), IBB: 383.01 (+9.43)

Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.18 (-0.10), SGYP: 8.30 (+0.11), MNK: 123.12 (+0.04), BIIB: 317.44 (+8.01), OCAT: 4.29 (-0.34), VRX: 257.80 (+0.50), PRGO: 190.15 (-3.45), VRTX: 126.78 (+3.55), GALT: 2.66 (+0.03), IBB: 383.01 (+9.43), MNKD: 4.92 (+0.15), HNT: 66.07 (+0.47), CELG: 135.86 (+3.30), CNC: 69.64 (+0.54), JNJ: 98.97 (+0.69), MDCO: 33.79 (+0.40), GILD: 112.98 (+2.44), GERN: 4.19 (+0.11), JUNO: 49.06 (+1.26), BXLT: 30.20 (-0.40), EXEL: 5.53 (+0.09), NVS: 102.65 (+1.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 188

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 164

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 149

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

New York Court Upholds Healthcare Rights for Retirees

Updated Category News Views 94

New York Court of Appeals Decision on Retiree Healthcare Rights In a landmark ruling, the New York Court of Appeals determined that the city is required to cover the total cost of the health insurance plans chosen by its retirees. This decision represents a significant win for over 250,000 retired workers and their families seeking to maintain their healthcare benefits....

Continue Reading
Corning's Strategic Path Amid AI Trends and Market Challenges

Updated Category News Views 1824

Corning Incorporated (NYSE: GLW) hit a crossroads back in 2024 as it tried to balance rising AI trends with challenges lurking in traditional markets. Renowned for its expertise in materials science, particularly specialty glass and optical physics, Corning was looking to leverage these trends while facing stiff competition and economic uncertainties. Quarterly...

Continue Reading
Innovating the Future: The Inaugural Global Quantum Forum

Updated Category News Views 274

Inaugural Global Quantum Forum Set to Launch During TechChicago Week The upcoming Global Quantum Forum promises to be a landmark event for the quantum industry, coinciding with the much-anticipated TechChicago Week. This two-day conference is positioned to take place in an exciting environment where innovation meets collaboration. With over 70 distinguished speakers,...

Continue Reading
Oil Prices React to US Supply and Rising Geopolitical Risks

Updated Category News Views 83

Oil Market Overview: Supply Dynamics and Geopolitical Tensions As oil prices faced a dip recently, analysts found that U.S. supply levels play a significant role in shaping market trends. The weekly report reflecting increased U.S. crude and gasoline stocks was a key factor influencing the downturn. Insights on Current Oil Price Performance Brent crude futures for January...

Continue Reading
Senator McConnell's Recent Stock Purchase Insights and Implications

Updated Category News Views 160

Insights into Senator McConnell's Stock Purchase Recently, it has come to public attention that Senator A. Mitchell McConnell, Jr. has made a notable financial move by purchasing stock in Wells Fargo (NYSE: WFC). This purchase, reported to be valued between $1,001 and $15,000, is part of a pattern of trading activity that might have implications for investors and stock...

Continue Reading